LA JOLLA, Calif.--(BUSINESS WIRE)--Chronix Biomedical announced that it has filed a provisional patent application for the precise measurement of cell-free DNA (cfDNA) in plasma using Digital PCR technology as a way to monitor the medical status of patients with transplanted organs or cancer through a liquid biopsy. Digital PCR is a new approach to cfDNA detection and quantification because it directly counts the number of target cfDNA molecules rather than comparing results to reference standards. The challenges associated with this approach relate to the difficulty to standardize cfDNA measurements due to low concentrations and the variable fragment sizes of cfDNA. Today, Prof. Dr. Ekkehard Schuetz (FACB), Chief Technology Officer of Chronix Biomedical, is a plenary speaker at the Digital PCR conference being held from October 6 to 8 in La Jolla, CA, USA and will show results from a new proprietary methodology that improves the Digital PCR quantification of cfDNA in his presentation entitled "Diagnostic Use of Digital PCR for Liquid Biopsy."
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.